Protein kinase C (PKC) is the family of serine/threonine kinases that read the lipid second messengers diacylglycerol (DAG) and calcium: conventional isoforms (α, βI/βII, γ) need both, novel isoforms (δ, ε, η, θ) DAG alone, atypical ones (ζ, ι/λ) neither — regulation by domain architecture rather than by one switch. Discovered as the receptor for tumor-promoting phorbol esters, PKC became the archetype of lipid-activated kinases: GPCR → phospholipase C → DAG/Ca2+ → PKC → ERK and gene expression, running platelets, secretion, contraction, and memory with ion-channel and hormone-receptor wiring.
Gene
PRKCA–G, PRKCH, PRKQ, PRKCI (nine genes)
Family
AGC kinases — PKC family
Location
Cytosol → membrane on DAG/Ca2+; some nuclear pools
The N-terminal regulatory half carries the C1 domains (the phorbol-ester/DAG binding zinc-fingers) and, in conventional PKCs, the C2 calcium domain — together they clamp the catalytic half inactive until lipid and calcium open them.
Translocation is the activation story: agonists move PKC from cytosol to plasma membrane within seconds — the original "pleckstrin translocation" of the field.
Novel PKCs lack C2 (no calcium dependence), atypical PKCs lack the C1's ligand competence — the family's three tiers of input gating.
Function
Receptor relay: Gq-coupled receptors activate phospholipase Cβ, growth-factor receptors PLCγ — both make IP3 (calcium) and DAG, the twin PKC inputs.
Downstream: PKC phosphorylates MARCKS, Raf (feeding the MAPK cascade), and transporters — secretion, contraction, and gene expression within minutes.
Tissue programs: PKCα in platelets and vascular signalling, PKCβ in diabetic retinopathy's VEGF axis, PKCθ in T-cell activation, PKCγ in neuronal plasticity.
Regulation
Priming phosphorylations (PDK1 on the activation loop, mTORC2-adjacent on the turn and hydrophobic motifs) mature the enzyme before DAG can open it — see PDK1's other client.
DAG lifetime caps the signal; diacylglycerol kinases terminate it. Phorbol esters, being non-metabolisable DAG mimics, keep PKC on until the enzyme is degraded — down-regulation, the tumor-promoter paradox's resolution.
RACK scaffold proteins direct isoforms to substrates; phosphorylation state and caspase cleavage (of PKCδ especially) re-target the family in apoptosis.
Interactions
With calcium signalling: IP3-receptor calcium release and C2 binding couple PKC to the same ER store that ion pumps refill.
With the Raf-MEK-ERK route: PKC's Raf phosphorylation is the phorbol-ester growth response — the bridge to ERK.
With Gq-coupled hormone receptors: the signaling cascade that vasopressin and angiotensin use in vascular smooth muscle.
Clinical Relevance
Diabetes complications: ruboxistaurin (PKCβ inhibitor) — diabetic macular oedema therapy in Japan — the family's flagship approval.
Cancer: phorbol promoters and PKC isoform dysregulation gave the family its oncology reputation; outcomes by isoform split (PKCδ suppresses; PKCι/λ sustains stem-like programs) — midostaurin (multi-kinase incl. PKC) approved in AML.
Neurology and immunology: PKCγ spinocerebellar ataxia mutations; PKCθ inhibitors sought in autoimmunity — the isoform map keeps guiding trials.